Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subdistribution hazard ratio (SHR) of GC with statins was calculated by competing risk regression with propensity score (PS) analysis matching 19 variables (age, sex, comorbidities and other drug usage including proton pump inhibitors, non-steroidal anti-inflammatory drugs, aspirin, cyclooxygenase-2 inhibitors, and metformin).
|
31792089 |
2020 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells.
|
31491956 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 and MMP-13 can be used as reference indexes to guide the treatment of gastric cancer and predict the disease prognosis.
|
30941969 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, we demonstrated that combinatorial inhibition of COX-2 and DNMT using Celecoxib and Decitabine synergistically inhibited GC growth <i>in vitro</i> and <i>in vivo</i>.
|
31534549 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Double IHC staining showed that TAMs were aggregated near GC tumor nests and had high COX2 expression; moreover, the number of TAMs that infiltrated the tumor nest was correlated with the depth of invasion, COX2 expression and poor prognosis in human GC.
|
31632572 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis of 15 case-control studies provides strong evidence that the COX-2 rs20417 polymorphism increases the risk of GC susceptibility in general populations, especially in Asians.
|
31045826 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer.
|
31473273 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 and MMP-13 can be used as reference indexes to guide the treatment of gastric cancer and predict the disease prognosis.
|
30003735 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
This work aimed to study COX-2 methylation and expression in N-methyl-N-Nitrosurea (MNU)-induced intestinal GC in six Sapajus apella animals.
|
29767663 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The COX2 -1195G > A polymorphism showed significant correlation with gastric cancer susceptibility in total analysis, and stratification analysis by ethnicity also revealed a similar association in both Asian and Caucasian groups under the same contrast.
|
30391440 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer.
|
31518663 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results revealed that CDH1, cyclooxygenase-2 and matrix metalloproteinase genes had significantly higher expression levels, whereas the expression levels of dermatopontin and transforming growth factor β receptor 2 were decreased in GC samples.
|
29434905 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined administration of γ-secretase and COX-2 inhibitor produced a marked inhibition of growth in AGS cells, which suggests that patients with poorly differentiated GC may benefit from the blockage of NICD, which potentially serves a role in GC differentiation.
|
29616098 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate the unregulated expression of ANXA1 and COX-2 in precursor lesions of esophageal and stomach cancers, reinforcing their involvement in gastroesophageal carcinogenesis.
|
29254791 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compound Wumei Powder Inhibits the Invasion and Metastasis of Gastric Cancer via Cox-2/PGE2-PI3K/AKT/GSK3<i>β</i>/<i>β</i>-Catenin Signaling Pathway.
|
29358963 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis results showed that the COX-2 -1195G>A gene polymorphism significantly correlated with an increased risk of gastrointestinal cancers, particularly gastric cancer (A <i>vs</i> G: OR = 1.35; AA/AG <i>vs</i> GG: OR = 1.54; AA <i>vs</i> GG/AG: OR = 1.43; AA <i>vs</i> GG: OR = 1.80; AG <i>vs</i> GG: OR = 1.35).
|
28405152 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Curcumin Enhances the Anticancer Effect Of 5-fluorouracil against Gastric Cancer through Down-Regulation of COX-2 and NF- κB Signaling Pathways.
|
29151957 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cell proliferation and migration experiments were conducted on the RhoA-silenced A6-B9 cells and COX-2-silenced D7-B8 cells so as to discuss their role in the development of gastric cancer.
|
28624843 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 180 cases of GC, the clinicopathologic features were correlated with the results obtained after paired immunohistochemical stains (tumor/normal mucosa) with 15 antibodies: E-cadherin, HER-2, VEGF, CD31, CD105, COX-2, maspin, bax, bcl-2, p53, Ki67, MLH-1, MSH-2, Mena protein, and vimentin.
|
26067133 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the overexpression of transcription factor C/EBPβ in gastric cancer interacted with NFκB and further regulates COX-2 expression.
|
26514342 |
2016 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings emphasize the importance of COX-2 as a potential marker of tumor progression and prognosis in GC, and that the inhibition of COX-2 activity may have a therapeutic benefit in GC.
|
27314294 |
2016 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
A pathway analysis of human gastric cancer shows that both the COX-2 pathway and Wnt/β-catenin signaling are significantly activated in tubular-type gastric cancer, and basal levels of these pathways are also increased in other types of gastric cancer.
|
27079437 |
2016 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although an association between candidate SNPs and gastric cancer was not found in Peruvians, trend in our data is consistent with meta-analyses results that suggest PTGS2-rs689466-A is associated with H. pylori-associated gastric cancer in East Asia.
|
26391267 |
2016 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alterations of Cyclooxygenase-2 Methylation Levels Before and After Intervention Trial to Prevent Gastric Cancer in a Chinese Population.
|
27020655 |
2016 |
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
No significant association was found between COX-2 methylation and risk of GC (OR, 1.15; 95% CI: 0.70-1.88).
|
26674784 |
2015 |